New MS drug trial for kids: could ocrelizumab help?
NCT ID NCT07503340
First seen Jun 27, 2026 · Last updated Aug 07, 2026 · Updated 3 times
Summary
This study tests a drug called ocrelizumab in children and teens aged 10 to 17 with relapsing-remitting multiple sclerosis (MS). The goal is to see how the drug moves through the body, if it is safe, and how it affects the immune system. Participants will receive the drug as a shot under the skin and be followed for up to 2 years. This is an early-phase trial with 25 participants, so it focuses on safety and dosing rather than a cure.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSING-REMITTING MULTIPLE SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Hidden MS progression: can brain scans and blood tests predict it?
- Can a new MRI scan reveal the Brain's hidden repair process in MS?
- Walking workouts may sharpen the MS brain — a trial puts it to the test
- Can a simple obstacle course reveal hidden links between fatigue and walking trouble in MS?
- Can sensing wrist position unlock better hand control in MS?
- AI-Powered tool aims to sharpen MS treatment choices